Kinase News and Research

RSS

New test to help physicians identify patients with most lethal forms of triple-negative breast cancer

A new test has the potential to help physicians identify patients with the most lethal forms of triple-negative breast cancer, a disease which requires aggressive and innovative treatment.

12 Dec 2013

Researchers find decreased energy metabolism in heart cells as significant independent risk factor

Johns Hopkins researchers have identified a new way to predict which heart failure patients are likely to see their condition get worse and which ones have a better prognosis. Their study is one of the first to show that energy metabolism within the heart, measured using a noninvasive magnetic resonance imaging test, is a significant predictor of clinical outcomes, independent of a patient's symptoms or the strength of the heart's ability to pump blood, known as the ejection fraction.

11 Dec 2013

Pharmacyclics presents ibrutinib trial data for B-cell malignancies at ASH meeting

Pharmacyclics, Inc. today announced results of 40 clinical, non-clinical and pre-clinical presentations on ibrutinib (IMBRUVICA™) at the 55TH Annual meeting of the American Society of Hematology (ASH) held in New Orleans, Dec 7 - 10, 2013.

11 Dec 2013

Acetylon announces positive preclinical data of ricolinostat (ACY-1215) in models of lymphoma

Acetylon Pharmaceuticals, Inc., the leader in the development of selective histone deacetylase (HDAC) inhibitors for enhanced therapeutic outcomes, announced that positive preclinical data of selective HDAC6 inhibitor, ricolinostat (ACY-1215), in models of lymphoma were presented today in an oral presentation by Dr. Jennifer Amengual, Assistant Professor of Medicine & Experimental Therapeutics, Columbia University Medical Center.

10 Dec 2013

Novel multi-kinase inhibitor shows early promise in NSCLC

Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer.

9 Dec 2013

Gene discovered to play a part in one per cent of all cancers

Researchers have identified a gene that drives the development of tumours in over one per cent of all cancer patients. This is the first time that the gene CUX1 has been broadly linked to cancer development.

9 Dec 2013

PKM2 protein controls mitosis, saving cancer cells from death and promoting brain tumor growth

Researchers have caught a protein they previously implicated in a variety of cancer-promoting roles performing a vital function in cell division, survival and development of brain tumors.

8 Dec 2013

Kolltan Pharmaceuticals signs license agreement with University of Toronto for novel anti-KIT antibodies

Kolltan Pharmaceuticals, a privately held biopharmaceutical company, today announced the Company has signed a license agreement with the University of Toronto for novel anti-KIT receptor tyrosine kinase antibodies identified in the laboratories of Dr. Sachdev Sidhu at the University of Toronto and the laboratory of Dr. Joseph Schlessinger of Yale University.

6 Dec 2013

Study reveals that brain cancer cells resist therapy by dialing down gene mutation targeted by drugs

A team of scientists, led by principal investigator Paul S. Mischel, MD, a member of the Ludwig Institute for Cancer Research and professor in the Department of Pathology at the University of California, San Diego School of Medicine, has found that brain cancer cells resist therapy by dialing down the gene mutation targeted by drugs, then re-amplify that growth-promoting mutation after therapy has stopped.

6 Dec 2013

Findings suggest new approach for treating inflammatory bone diseases and skeletal metastases

The skeleton is constantly being remodelled by the breakdown of old bone by cells called osteoclasts and the formation of new bone by cells called osteoblasts. This coordinated activity is essential for maintaining healthy bone. However, excessive osteoclast activity leads to bone destruction in skeletal diseases such as osteoporosis, rheumatoid arthritis and cancer metastases in bone. A family of signaling enzymes known as phosphatidylinositol 3-kinases control diverse cell functions but, up until now, little was known about the function of specific PI3K isoforms in osteoclasts.

5 Dec 2013

TLR4 antibody-mediated signaling system in apoptosis of hippocampal neurons

Toll-like receptor 4 (TLR4) antibody, protein kinase B (AKT) inhibitor, LY 294002, and glycogen synthase kinase 3β (GSK-3β) inhibitor, LiCl, were used by Yu He and colleagues from Nantong University, China to attenuate or augment the effects of the TLR4-phosphatidylinositol 3 kinase (PI3K)/AKT-GSK-3β signaling pathway so as to identify the participation of this signaling system in the apoptosis of hippocampal neurons.

5 Dec 2013

Investigational c-Met inhibitor shows early promise in NSCLC

A first-in-class drug that inhibits c-Met, a receptor tyrosine kinase, has demonstrated good tolerability when combined with erlotinib in the treatment of Japanese patients with advanced/metastatic non-small-cell lung cancer.

3 Dec 2013

USC scientists show gene-environment interaction augments risk for developing autism

Exposure to air pollution appears to increase the risk for autism among people who carry a genetic disposition for the neurodevelopmental disorder, according to newly published research led by scientists at the Keck School of Medicine of the University of Southern California.

2 Dec 2013

Scientists identify new approach to fight malaria parasites

Using advanced methodologies that pit drug compounds against specific types of malaria parasite cells, an international team of scientists, including researchers at the University of California, San Diego School of Medicine and the Genomics Institute of the Novartis Research Foundation, have identified a potential new weapon and approach for attacking the parasites that cause malaria.

28 Nov 2013

Researchers identify protein in malaria that is inhibited by newly discovered anti-malarial compounds

Researchers have identified the protein in malaria-causing Plasmodium parasites that is inhibited by a newly discovered class of anti-malarial compounds known as imidazopyrazines.

28 Nov 2013

Findings highlight possible new approach to combat malaria

An international team of scientists, including researchers at Columbia University Medical Center, has identified a key metabolic enzyme that common malaria parasites require for survival at each stage of infection in humans. The findings raise the possibility of a new approach to combating malaria, one of the world's deadliest diseases. The study was published today in the online edition of the journal Nature.

27 Nov 2013

NEXAVAR tablets receive FDA approval for treatment of patients with thyroid cancer

Bayer HealthCare and Onyx Pharmaceuticals, Inc., an Amgen subsidiary, today announced that the U.S. Food and Drug Administration has approved a supplemental New Drug Application for the oral multi-kinase inhibitor NEXAVAR (sorafenib) tablets for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment.

23 Nov 2013

Targeting single enzyme in the obese could help prevent and treat diabetes

A single overactive enzyme worsens the two core defects of diabetes—impaired insulin sensitivity and overproduction of glucose—suggesting that a drug targeting the enzyme could help correct both at once, according to mouse studies done by researchers at Columbia University Medical Center. The findings were published today in the online edition of Cell Metabolism.

22 Nov 2013

Attractants prevent maturing nerve cells from migrating into brain

A vision is to implant nerve precursor cells in the diseased brains of patients with Parkinson's and Huntington's diseases, whereby these cells are to assume the function of the cells that have died off.

21 Nov 2013

Weill Cornell Medical College receives grant to support research efforts designed to end women's cancers

MasterCard today announced a $500,000 grant to Weill Cornell Medical College to support research efforts designed to end women's cancers.

19 Nov 2013